BSE Live
Sep 29, 16:01Prev. Close
5690.30
Open Price
5700.00
Bid Price (Qty.)
5670.00 (1)
Offer Price (Qty.)
5725.00 (1)
NSE Live
Sep 29, 14:18Prev. Close
5689.50
Open Price
5717.00
Bid Price (Qty.)
5678.00 (11)
Offer Price (Qty.)
5678.50 (8)
Profit & Loss account of Divis Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 9,325.00 | 7,796.00 | 7,665.94 | 8,799.23 | 6,858.34 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 9,325.00 | 7,796.00 | 7,665.94 | 8,799.23 | 6,858.34 | |
Total Operating Revenues | 9,360.00 | 7,845.00 | 7,767.51 | 8,959.83 | 6,969.40 | |
Other Income | 352.00 | 339.00 | 344.66 | 113.87 | 62.56 | |
Total Revenue | 9,712.00 | 8,184.00 | 8,112.17 | 9,073.70 | 7,031.96 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 3,821.00 | 3,232.00 | 3,008.36 | 3,476.56 | 2,397.44 | |
Purchase Of Stock-In Trade | 0.00 | 6.00 | 22.33 | 14.41 | 5.31 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FGWIP And Stock In Trade | -96.00 | -109.00 | 23.03 | -523.83 | -78.67 | |
Employee Benefit Expenses | 1,243.00 | 1,094.00 | 975.02 | 946.16 | 825.76 | |
Finance Costs | 2.00 | 3.00 | 0.67 | 0.80 | 0.87 | |
Depreciation And Amortisation Expenses | 402.00 | 378.00 | 343.18 | 311.51 | 255.59 | |
Other Expenses | 1,424.00 | 1,417.00 | 1,370.95 | 1,164.59 | 959.62 | |
Total Expenses | 6,796.00 | 6,021.00 | 5,743.54 | 5,390.20 | 4,365.92 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 2,916.00 | 2,163.00 | 2,368.63 | 3,683.50 | 2,666.04 | |
Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Profit/Loss Before Tax | 2,916.00 | 2,163.00 | 2,368.63 | 3,683.50 | 2,666.04 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 799.00 | 514.00 | 439.17 | 644.00 | 616.46 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | -74.00 | 49.00 | 106.08 | 79.05 | 65.29 | |
Other Direct Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 725.00 | 563.00 | 545.25 | 723.05 | 681.75 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 2,191.00 | 1,600.00 | 1,823.38 | 2,960.45 | 1,984.29 | |
Profit/Loss From Continuing Operations | 2,191.00 | 1,600.00 | 1,823.38 | 2,960.45 | 1,984.29 | |
Profit/Loss For The Period | 2,191.00 | 1,600.00 | 1,823.38 | 2,960.45 | 1,984.29 | |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Consolidated Profit/Loss After MI And Associates | 2,191.00 | 1,600.00 | 1,823.38 | 2,960.45 | 1,984.29 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 83.00 | 60.00 | 69.00 | 112.00 | 75.00 | |
Diluted EPS (Rs.) | 83.00 | 60.00 | 69.00 | 112.00 | 75.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 796.00 | 796.00 | 796.41 | 530.94 | 0.00 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
10.09.2025
Reduce Divis Laboratories; target of Rs 5400: Geojit Financial Services
07.08.2025
Accumulate Divis Laboratories; target of Rs 6550: Prabhudas Lilladher
07.08.2025
Divis Labs Standalone June 2025 Net Sales at Rs 2,357.00 crore, up 14.25% Y-o-Y
23.05.2025
Accumulate Divis Laboratories; target of Rs 7518: Deven Choksey
07.08.2025
Divis Labs Standalone June 2025 Net Sales at Rs 2,357.00 crore, up 14.25% Y-o-Y
19.05.2025
Divis Labs Consolidated March 2025 Net Sales at Rs 2,585.00 crore, up 12.24% Y-o-Y
19.05.2025
Divis Labs Standalone March 2025 Net Sales at Rs 2,536.00 crore, up 12.26% Y-o-Y
03.02.2025
Divis Labs Consolidated December 2024 Net Sales at Rs 2,319.00 crore, up 25.01% Y-o-Y
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill